| Report ID | 280630 |
| Drug Identification Number | 02244947 |
| Brand name | KETOROLAC TROMETHAMINE INJECTION, USP |
| Common or Proper name | KETOROLAC TROMETHAMINE INJECTION, USP |
| Company Name | FRESENIUS KABI CANADA LTD |
| Market Status | MARKETED |
| Active Ingredient(s) | KETOROLAC TROMETHAMINE |
| Strength(s) | 30MG |
| Dosage form(s) | LIQUID |
| Route of administration | INTRAMUSCULAR INTRAMUSCULAR |
| Packaging size | 1 mL |
| ATC code | M01AB |
| ATC description | ANTIINFLAMMATORY/ANTIRHEUMATIC PROD.,NON-STEROIDS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2026-03-25 |
| Actual start date | |
| Estimated end date | 2026-06-15 |
| Actual end date | |
| Shortage status | Anticipated shortage |
| Updated date | 2026-03-16 |
| Company comments | Fresenius Kabi Canada regrets to advise that due to a delay in production, we will encounter a backorder on our Ketorolac Tromethamine Injection, USP 30 mg/mL, 1 mL Vial effective March 25, 2026, until June 15, 2026. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
| Company contact information |
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v2 | 2026-03-16 | French | Compare |
| v1 | 2026-03-16 | English | Compare |
Showing 1 to 2 of 2